Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06988150 · ClinicalTrials.gov registry record

Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

A clinical trial of Weight Loss and Pancreatic Adenocarcinoma, sponsored by Cedars-Sinai Medical Center.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT06988150: Recruiting study of Weight Loss and Pancreatic Adenocarcinoma, sponsored by Cedars-Sinai Medical Center.

NCT06988150 is a study of Weight Loss and Pancreatic Adenocarcinoma that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 100 participants, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06988150, a study of Weight Loss and Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.

Primary Outcome

Assess the prevalence of SIBO in consecutive PDAC patients with clinically significant weight loss.

Study Locations (1)

California

  • Cedars-Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-04-14
Est. Completion 2026-04-14
Cedars-Sinai Medical Center

339 total trials

What NCT06988150 shows while recruiting

NCT06988150 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Weight Loss appearing as the primary indexed condition, and to 0 interventions.

NCT06988150 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06988150 about?

NCT06988150 is a clinical study titled "Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)". The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with...

What is the current status of trial NCT06988150?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-04-14. Estimated completion is 2026-04-14.

What conditions does trial NCT06988150 study?

This clinical trial studies the following conditions: Weight Loss, Pancreatic Adenocarcinoma.

Who is sponsoring clinical trial NCT06988150?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06988150 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Weight Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06988150's enrollment target sits among peer trials

100 48th of 116 higher than 66 of 116 other Weight Loss trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06988150, the US trial registry maintained by the National Library of Medicine. NCT06988150 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.